title: Predictors of Triptan Response in Pediatric Migraine.
abstract: Migraine is common in children and adolescents and can be disabling. Being able to predict which patients will respond to triptans based on their clinical phenotype would be helpful. Adult data suggest cranial autonomic symptoms and aura predict triptan response. This study examined clinical predictors of triptan response in pediatric migraineurs.
  
  
  
  This chart review study included all patients less than 18 years old with migraine who were seen at the University of California, San Francisco Headache Center in 2014. Univariate χ(2) analyses were performed, followed by multivariate logistic regression modeling.
  
  
  
  Of 127 pediatric migraineurs, 70 (55%) had chronic migraine and 24 (19%) had aura. The majority (55%) had at least one cranial autonomic symptom. Of 65 with triptan outcome data, 47 (73%) benefitted from a triptan. In univariate analyses, triptan benefit was seen in 65% with chronic migraine versus 88% with episodic migraine (P = 0.048), 67% with aura versus 74% without (P = 0.66), and 70% with cranial autonomic symptom versus 74% without (P = 0.76). In a multivariate logistic regression model, chronic migraine, aura, and cranial autonomic symptom were not statistically significant predictors of triptan benefit: chronic migraine: 0.25 (0.06-1.04); aura: 0.65 (0.09-4.45); cranial autonomic symptom: 0.75 (0.22-2.52).
  
  
  
  In univariate analysis, individuals with chronic migraine were less likely to benefit from triptans. In contrast to what has been documented in adults, cranial autonomic symptoms and aura did not predict triptan response, although our small sample size limited the study's power. Larger pediatric studies are needed, and future pediatric triptan trials should provide response rates stratified by clinical variables such as aura.
authors.affiliation: Vanderbilt University School of Medicine, Nashville, Tennessee.
authors.forename: Hannah F
authors.initials: HF
authors.lastname: Johnson
authors.affiliation: The Clinical Research Facility, Headache Center, Department of Neurology, University of California, San Francisco, California; The Clinical Research Facility, Headache Group, NIHR-Wellcome Trust Clinical Research Facility, King's College London, UK.
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Goadsby
authors.affiliation: The Clinical Research Facility, Headache Center, Department of Neurology, University of California, San Francisco, California; Division of Child Neurology, Department of Neurology, University of California, San Francisco, California. Electronic address: Amy.gelfand@ucsf.edu.
authors.forename: Amy A
authors.initials: AA
authors.lastname: Gelfand
mesh_terms: D000293:Adolescent; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D008881:Migraine Disorders / Q000175:diagnosis* / Q000188:drug therapy*; D015999:Multivariate Analysis; D011379:Prognosis; D018490:Serotonin Agents / Q000627:therapeutic use*; D016896:Treatment Outcome; D014363:Tryptamines / Q000627:therapeutic use*
chemical_list: D018490:Serotonin Agents; D014363:Tryptamines
keywords: aura; cranial autonomic symptoms; migraine; pediatrics; triptan